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1. INTRODUCTION 
Somatostatin (SRIF) has been shown to inhibit 
not only growth hormone secretion, but also the 
release of prolactin (PRL) both in vivo and in vitro 
[1-5]. On the other hand, vasoactive intestinal 
peptide (VIP) has been reported to stimulate speci- 
fically PRL release from rat pituitary lactotrophs 
[6]. It appears that this effect is mediated by cyclic 
AMP (cAMP) [7,8]. Here, we investigated whether 
SRIF can interact with the stimulatory effect of 
VIP on PRL release by rat pituitary cells in cul- 
ture, and whether this action is mediated by a 
modification of the cAMP accumulation i duced 
by VIP. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Male Wistar rats (45-60 days old) were used. In 
each experiment, 20 anterior pituitaries were dis- 
persed enzymatically in minimal essential medium 
with Earle's salts containing 0.1% trypsin (1:250, 
Gibco) and 0.1% fatty-acid-free bovine serum al- 
bumin (BSA) for 2 h at 37°C at pH 7.5 in a sili- 
cone-treated Bellco spinner flask. After filtration 
to remove DNA and broken cells, and several 
washes, 2-2.5 × 105 cells were plated in 16 mm 
tissue culture wells (Costar) in 250 ~1 culture medi- 
um consisting in sterile medium 199 with Hank's 
salts (Gibco) containing 0.1% BSA, 25 mM Hepes, 
10% horse serum, 2.5% fetal calf serum, and anti- 
biotics, for 48 h at 37°C under 95% 02/5% C02. 
2.2. Incubation 
After 48 h, the culture medium was discarded 
and the cells were washed twice with filtered 
(0.45/tm Millipore) Krebs Ringer (pH 7.5) phos- 
phate buffer (118 mM NaCI; 5 mM KC1; 1.2 mM 
MgSO4; 1.2 mM KH2PO4; 10mM Na2HPO4) 
containing 0.02 mM bacitracin (Sigma) and 2% 
BSA. All incubations were performed in 250 ~1 of 
the same buffer at 25-26°C in the presence or ab- 
sence of SRIF (synthetic SRIF, Beckman) for 
15 min before the addition of highly purified por- 
cine VIP (V. Mutt, Stockholm). The incubation 
was stopped 15 min after VIP addition. This time 
point was chosen since it allowed us to measure 
both cAMP accumulation and PRL release in- 
duced by VIP on the same cells [8]. 
2.3. Assays 
Aliquots of the medium (20-30 #1) were taken 
for PRL measurement and the reaction was termi- 
nated by the addition of 25 ~1 1.1 M perchloric 
acid to the cells which were extracted for cAMP 
measurement by radioimmunoassay as in [8]. Me- 
dium PRL was measured by radioimmunoassay 
using reagents kindly supplied by the Pituitary 
Hormone Distribution Program (NIH) and Dr 
A.F. Parlow. 
To represent the data from both cAMP and PRL 
by the same cells on the same figure, results were 
expressed as % of VIP stimulation. Means +__ SEM 
were obtained from the individual values and sta- 
tistical analysis was performed by means of the 
non-parametric Friedman test [9]. 
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3. RESULTS 
As reported in [6,8], under similar experimental 
conditions, VIP induced a dose-dependent in- 
crease in cAMP accumulation and PRL release 
with a maximum increase occurring at 10-7 M. In- 
creasing [SRIF] from 10-10-10 6 M inhibited in 
a dose-dependent manner the stimulation of  both 
cAMP accumulation and PRL secretion induced 
by 10 7 M VIP (fig.l). Half-maximal inhibition 
for both cAMP accumulation and PRL secretion 
was obtained with -1 -2  × 10-1° M SRIF. 
However, if the cells are pretreated with 0.5 mM 
isobutylmethylxanthine (IBMX), a phosphodies- 
terase inhibitor, just before SRIF addition to the 
incubation medium, SRIF is able to dramatically 
inhibit PRL release induced by VIP without sig- 
nificantly counteracting the increase of  cAMP ac- 
cumulation induced by VIP (fig.2). Moreover, un- 
der these conditions, the dose-response curve of  
PRL secretion to VIP is attenuated by the presence 
of SRIF in the incubation medium 15 min before 
VIP (fig.3). SRIF at 5 × 10-7 M diminished the 
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Fig.2. Effect of increasing [SRIF] on 10 -7 M V1P-induc- 
ed stimulation of PRL release and cAMP accumulation 
(expressed as 100%) in the presence of 0.5 mM IBMX. 
For VIP stimulation of both PRL and cAMP, 100% is 
equal to 68 ± 10 ng/106 cells and 1.16 pmol/10 6 ceils, 
respectively, which represent 2.5- and 2.6-fold increases 
as compared to basal values. Results are shown as 
means ± SEM. Number of experimental points for each 
group are quoted. 
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Fig.l. Effect of increasing [SRIF] on 10 7 M VlP-induc- 
ed stimulation of PRL release and cAMP accumulation 
(expressed as 100%) in the absence of IBMX. For VIP 
stimulation of both PRL and cAMP, 100% is equal to 48 
__. 9 ng/106 cells and 0.58 ± 0.09 pmol/10 6 cells, respec- 
tively, which represent 3.4- and 2.3-fold increases as 
compared to basal values. Results are shown as means 
_ SEM. Number of experimental points for each group 
are quoted. 
maximal stimulation of  PRL release induced by 
VIP without significantly affecting the half-maxi- 
mal stimulation (fig.3). 
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Fig.3. Dose-dependent stimulation of VIP-induced PRL 
release in the presence or absence of 5 × 10 7 M SR|F 
with IBMX. Results are shown as means + SEM. Num- 
ber of experimental points are given in parentheses. 
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4. DISCUSSION 
These results show that VIP stimulation of PRL 
release by pituitary cells in culture can be modul- 
ated by SRIF. SRIF has been reported to inhibit 
the stimulation of PRL secretion by various neu- 
ropeptides uch as TRH and bombesin [1,4,10] 
and by VIP on rat hemipituitaries [11]. The inhibi- 
tory effect of SRIF reported here on pituitary cells 
is dose-dependent and occurs rapidly since it can 
be obtained when SRIF is added to the incubation 
medium only 15 rain before VIP. As reported for 
the inhibition of TRH-induced PRL release [1], the 
fact that SR1F blunts the maximal response of 
PRL release to VIP, without significantly affecting 
the apparent affinity of the effect, suggests that 
each peptide acts through separate receptor-bind- 
ing sites. This conclusion can be related to the ob- 
servation [12] that the specific binding of 125I- 
SRIF to pituitary membranes is not altered by 
VIP. This suggests that the possible interaction be- 
tween SRIF and VIP takes place distally to the re- 
ceptors. 
In [7,8] VIP receptors in the pituitary were cou- 
pled to cAMP, and the increase of cAMP ac- 
cumulation was related to stimulation of PRL se- 
cretion [7,8]. However, conflicting data have been 
reported regarding the involvement of cAMP in 
the mechanism of action of SRIF [13]. The correla- 
tion in the absence of a phosphodiesterase inhibi- 
tor between the inhibition by SRIF of cAMP ac- 
cumulation and VIP-stimulated PRL release might 
be interpreted as indicating that the partial inhibi- 
tory effect of SRIF on VIP-induced PRL secretion 
is mediated by an inhibition of cAMP accumula- 
tion. However, the fact that, in the presence of 
IBMX, the inhibition by SRIF of PRL secretion 
induced by VIP is still observed and is even 
stronger, whereas cAMP is not significantly re- 
duced, give little support o this hypothesis. These 
results with IBMX suggest hat the effect of SRIF 
is not on the cAMP production, but indeed on a 
more distal step. 
A possible alternative xplanation however, for 
the dissociation observed in the presence of IBMX 
between cAMP accumulation on the one hand and 
PRL release induced by VIP on the other, is that 
SRIF may influence only a small portion of the in- 
tracellular cAMP pool, a portion which might be 
localized on the phosphorylation-dephosphoryla- 
tion processes carried out by cAMP-dependent 
protein kinases [14]. Indeed, VIP was effective in 
stimulating cAMP-dependent protein kinases in 
isolated intestinal epithelial cells [15]. However, 
this effect could be difficult to detect when total 
cAMP is measured, as in these data, but still be 
efficient enough to affect PRL secretion. In the 
distal step, SRIF may have other actions: it could 
modify, for instance, the activity of the phos- 
phodiesterase. However, if it would be the case, 
PRL secretion induced by VIP will not be affected 
by SRIF as for cAMP accumulation (fig.2). Fi- 
nally, we cannot exclude the possibility that SRIF 
may act on the mobilization of intracellular cal- 
cium which may indirectly result in an impairment 
of the cyclic nucleotide metabolism [13]. Further 
work is now required to test these different pos- 
sibilities, 
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